Amgen Inc. (AMGN) Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar Candidate [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
Amgen Inc. (NASDAQ: AMGN is one of the 10 best stocks to invest in during a recession Amgen Inc. (AMGN) Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar Candidate On February 27, 2026, Amgen Inc. (NASDAQ:AMGN)'s Phase 3 study (NCT05907122) saw an update. The study investigating ABP 206, a biosimilar candidate for Opdivo (nivolumab), has officially reached Completed status. The trial enrolled 256 subjects with resected stage III or IV melanoma to demonstrate pharmacokinetic similarity and clinical efficacy over a 12-month adjuvant period. The primary completion was reached in March 2025, and final updates were posted in late February 2026. Data is likely being analyzed to support regulatory filings. If successful, ABP 206 could establish Amgen Inc. (NASDAQ:AMGN) as a key provider of lower-cost immunotherapy for advanced melanoma. On February 19, 2026, Wells Fargo raised the price target on Amgen Inc. (NASDAQ:AMGN) from $325 to $375 while maintaining an Equal Weight rating.
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen (AMGN) had its price target raised by Wells Fargo & Company from $375.00 to $390.00. They now have an "equal weight" rating on the stock.MarketBeat
- Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies [Yahoo! Finance]Yahoo! Finance
- Amgen's TrumpRx Discounts and Dividend Hike Might Change The Case For Investing In Amgen (AMGN) [Yahoo! Finance]Yahoo! Finance
- Amgen and GSK said to be adding products on TrumpRx [Seeking Alpha]Seeking Alpha
AMGN
Earnings
- 2/3/26 - Beat
AMGN
Sec Filings
- 3/18/26 - Form 4
- 3/18/26 - Form 4
- 3/18/26 - Form 4
- AMGN's page on the SEC website